🔎 Trials Near Me

Beranda › Defisiensi Alfa-1 Antitripsin › South Carolina

Uji klinis Defisiensi Alfa-1 Antitripsin di South Carolina

6 studi untuk Defisiensi Alfa-1 Antitripsin mencari peserta di lokasi di South Carolina.

Kota di South Carolina

Teks studi resmi (Bahasa Inggris)

A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)

  • Clinical Study Center, Charleston
Menerima pesertaFase 1/2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT06389877

A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)

  • Clinical Study Center, Charleston
Menerima pesertaFase 1/2
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT07227207

A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)

  • GC2501 Study Site 101, Charleston
Menerima pesertaFase 3
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT07555483

A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems

  • University of South Carolina, Charleston
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Jul 2026 · NCT06512454

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

  • Medical University of South Carolina, Charleston
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 13 Mei 2026 · NCT05677971

A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency

  • Medical University of South Carolina, Charleston
Menerima pesertaFase 1
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 22 Jul 2025 · NCT06049082

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.